Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen

Monday, the Centers for Medicare & Medicaid Services (CMS) is prepared to ease the limits on its coverage of PET scans for detecting amyloid plaques in the brains of patients with Alzheimer’s disease. If the proposed change goes into effect, it could mean better business for Eisai, Biogen and other drugmakers whose new Alzheimer’s treatments require such scans.